On April 15, 2026 Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to advance cancer therapy selection, reported that it will present new data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, California. The five presentations will highlight the power of Arima’s Hi-C sequencing-based approach to detect clinically relevant structural variants and uncover important drivers of cancer across solid tumors. Together, they reflect Arima’s vision for expanding cancer genomics beyond sequence alone.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Structural variants are an important driver of cancer biology, and Arima is focused on bringing that dimension into cancer genomics," said Anthony Schmitt, PhD, Senior Vice President of Science at Arima Genomics. "The data we will present at AACR (Free AACR Whitepaper) reflect the breadth of that opportunity across solid tumors."
The presentations include data demonstrating Arima’s ability to detect structural variants in lung and gastrointestinal tumors, showing concordance with traditional methods while also identifying variants those methods may miss. That capability, demonstrated across multiple studies, underpins Arima’s Aventa FusionPlus clinical assay. Additional presentations demonstrate the ability to detect and predict the functional impact of enhancer hijacking rearrangements and extrachromosomal DNA (ecDNA) amplifications in non-small cell lung cancer (NSCLC). A fifth presentation extends Arima’s work in fusion and rearrangement detection into gynecologic carcinosarcoma through analysis of aberrations involving genes potentially linked to homologous recombination deficiency (HRD). Together, the AACR (Free AACR Whitepaper) data show the range of biological and clinical questions that a structural variant-focused approach can address.
"These studies show how Arima’s technology provides a new lens with which to view the cancer genome in a way that no other technology can," said Tom Willis, PhD, Chief Executive Officer of Arima Genomics. "We are already putting this approach to work for patients through our Aventa clinical tests, while continuing to build the evidence and applications that support a more complete view of cancer."
List of Poster Presentations
April 20, 2026, 2:00-5:00 PM
Detection and functional assessment of extrachromosomal DNA amplifications in FFPE lung tumor specimens using Hi-C sequencing
Poster Number: 3259
Location: Section 22
Discovery and functional characterization of enhancer hijacking oncogene rearrangements in NSCLC using Hi-C sequencing of FFPE tumors
Poster Number: 3747
Location: Section 41
Fusions and rearrangement detection in gastrointestinal and lung tumors leveraging low-pass whole-genome sequencing based Hi-C chemistry
Poster Number: 3817
Location: Section 44
Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status
Poster Number: 3970
Location: Section 49
April 21, 2026, 2:00-5:00 PM
Actionable fusions and rearrangements can be efficiently identified by Hi-C whole genome sequencing in lung tumors
Poster Number: 6521
Location: Section 43
(Press release, Arima Genomics, APR 15, 2026, View Source [SID1234664423])